Rizwan Romee

Hematology | Oncology

450 Brookline Avenue
Boston, MA 02115

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 143 publications

Accelerating Translation of NK Cell Therapies to the Clinic: A European Perspective.

Accelerating Translation of NK Cell Therapies to the Clinic: A European Perspective.

Journal: Human gene therapy

Published: August 03, 2026

Beyond autologous ex vivo CAR-expressing cell therapies: Toward allogeneic and nucleated cell-free delivery systems of CAR.

Beyond autologous ex vivo CAR-expressing cell therapies: Toward allogeneic and nucleated cell-free delivery systems of CAR.

Journal: Molecular therapy. Oncology

Published: March 05, 2026

Reprogramming Antitumor Immunity: NK Cell Strategies to Navigate the Immunosuppressive Tumor Microenvironment.

Reprogramming Antitumor Immunity: NK Cell Strategies to Navigate the Immunosuppressive Tumor Microenvironment.

Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)

Published: February 20, 2026

Publisher Correction: Surface expression of antitoxin on engineered bacteria neutralizes genotoxic colibactin in the gut.

Publisher Correction: Surface expression of antitoxin on engineered bacteria neutralizes genotoxic colibactin in the gut.

Journal: Nature microbiology

Published: December 23, 2025

Impact of Post-Transplant Cyclophosphamide on the Prognostic Value of HCT-CI.

Impact of Post-Transplant Cyclophosphamide on the Prognostic Value of HCT-CI.

Journal: Transplantation and cellular therapy

Published: November 22, 2025

eGFR Discordance and Its Association with Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation and Adoptive T-Cell Therapies.

eGFR Discordance and Its Association with Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation and Adoptive T-Cell Therapies.

Journal: Journal of the American Society of Nephrology : JASN

Published: November 20, 2025

Baseline IPSS-M vs Pretransplant Risk Downstaging as Prognostic Determinants in MDS Undergoing Allogeneic Transplantation.

Baseline IPSS-M vs Pretransplant Risk Downstaging as Prognostic Determinants in MDS Undergoing Allogeneic Transplantation.

Journal: Blood advances

Published: September 16, 2025

Baseline IPSS-M vs pretransplant risk downstaging as prognostic determinants in MDS undergoing allogeneic transplantation.

Baseline IPSS-M vs pretransplant risk downstaging as prognostic determinants in MDS undergoing allogeneic transplantation.

Journal: Blood advances

Published: September 16, 2025

No clear benefit of cellular therapy consolidation for patients achieving remission after post-HCT AML relapse.

No clear benefit of cellular therapy consolidation for patients achieving remission after post-HCT AML relapse.

Journal: Blood advances

Published: August 19, 2025

No clear benefit of cellular therapy consolidation for patients achieving remission after post-HCT AML relapse.

No clear benefit of cellular therapy consolidation for patients achieving remission after post-HCT AML relapse.

Journal: Blood advances

Published: August 19, 2025

Expression of HLA-B*35 is Associated With an Increased Risk of CMV Viremia and Clinically Significant CMV Infection following PTCy-Based Hematopoietic Cell Transplantation.

Expression of HLA-B*35 is Associated With an Increased Risk of CMV Viremia and Clinically Significant CMV Infection following PTCy-Based Hematopoietic Cell Transplantation.

Journal: Transplantation and cellular therapy

Published: June 13, 2025

Poor Engraftment After Posttransplant Cyclophosphamide Graft-Versus-Host Disease Prophylaxis in Patients With Myelofibrosis.

Poor Engraftment After Posttransplant Cyclophosphamide Graft-Versus-Host Disease Prophylaxis in Patients With Myelofibrosis.

Journal: American journal of hematology

Published: April 21, 2025

Showing 1-12 of 143

Last Updated: 09/26/2026